Free tool
FAERS Monitor: Fml Forte
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019216 or its brand name (Fml Forte, Fluorometholone). Reports on generic versions are filed under their own applications.
Reports
2,748
Serious
1,456
53% of reports
Hospitalization
731
Death reported
308
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure318
- fatigue201
- eye pain197
- drug ineffective192
- off label use187
- diarrhoea170
- headache168
- dyspnoea162
- arthralgia161
- condition aggravated146
- dizziness145
- pruritus139
- nausea138
- maternal exposure during pregnancy136
- asthenia135
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 5 |
| 2006 | 9 |
| 2007 | 9 |
| 2008 | 7 |
| 2009 | 15 |
| 2010 | 29 |
| 2011 | 28 |
| 2012 | 62 |
| 2013 | 46 |
| 2014 | 51 |
| 2015 | 68 |
| 2016 | 121 |
| 2017 | 125 |
| 2018 | 135 |
| 2019 | 147 |
| 2020 | 384 |
| 2021 | 173 |
| 2022 | 215 |
| 2023 | 229 |
| 2024 | 284 |
| 2025 | 330 |
| 2026 | 266 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,411 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 318 | 29.5 | 26.6 | 8,725 |
| eye painSignal | 197 | 26.8 | 23.4 | 4,866 |
| maternal exposure during pregnancySignal | 136 | 11.7 | 9.9 | 1,323 |
| condition aggravatedSignal | 146 | 3.7 | 3.1 | 286 |
| arthralgiaSignal | 161 | 3.0 | 2.6 | 212 |
| pruritusSignal | 139 | 2.8 | 2.4 | 158 |
| astheniaSignal | 135 | 2.7 | 2.3 | 151 |
| dizzinessSignal | 145 | 2.2 | 1.9 | 99 |
| dyspnoeaSignal | 162 | 2.2 | 1.9 | 106 |
| headacheSignal | 168 | 2.1 | 1.8 | 92 |
| diarrhoeaSignal | 170 | 2.0 | 1.7 | 89 |
| fatigue | 201 | 2.0 | 1.7 | 100 |
| off label use | 187 | 1.6 | 1.4 | 47 |
| nausea | 138 | 1.3 | 1.1 | 12 |
| drug ineffective | 192 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.